



Driving Success in Immuno-Oncology (IO) Development

Worldwide Clinical Trials has deep expertise in the development of transformative IO therapies. We partner with sponsors from early proof-of-concept through regulatory approval, helping advance innovative immuno-oncology treatments with precision, speed, and scientific rigor.

Conducting IO trials requires expertise in complex treatment modalities, novel study designs, biomarker-driven development strategies, and unique safety and toxicity profiles. Partnering with a CRO that understands these complexities is critical to accelerating development and bringing new therapies to patients faster.

Robust pipeline of immuno-oncology trials

Global Footprint

- Programs across North America, Europe, Asia-Pacific, Latin America, and the Middle East and North Africa

Study Experience

- 100+ IO studies in the last 5 years
- 13,300+ patients enrolled

IO Expertise

- >45% of our active oncology portfolio

Next-generation Drug Modalities

- Cell therapies (CAR-T, TILs)
 - Autologous & allogeneic
 - Hematologic malignancies & solid tumors
- Multi-specific antibodies
 - T/NK-cell & macrophage engagers
- Tumor microenvironment remodelers
- Oncolytic viruses & vaccines
- Gene therapies
- Novel checkpoint inhibitors

**>45%**

Of Our Active
Oncology
Portfolio

**100+**

IO Studies

**13,300+**

Patients
Enrolled

**Global
Footprint**

NA, EU, APAC,
LATAM, MENA

We understand immuno-oncology trials

- Complex modalities (cell therapies, bispecifics, and gene therapies)
- Complex endpoints & novel study designs (iRECIST, mTPI, and BOIN)
- Biomarker involvement and increased data collection
- Immune related safety/toxicity profiles (iAEs, CRS, ICANS/neurotoxicity, TLS, delayed reactions)
- Coordination of multiple vendors, complex trial logistics and drug handling procedures

What Sets Us Apart



Biotech Mindset Delivered Worldwide

We are purpose built around a biotech mindset that shapes both our partnership philosophy and delivery model, bringing the agility, responsiveness, and focus needed to meet critical oncology development milestones.



Oncology Expertise and Team Continuity

Oncology expertise is embedded across all functions, ensuring studies are led by professionals who understand the complexities of oncology science and trial execution. With an average of 11+ years of oncology experience across key roles and an industry-leading 90%+ retention rate in the oncology business unit, you can expect a seasoned, specialized team supporting your study end to end.



Flexible solutions
& best-in-class
technologies



Data-centric approach
with visual analytics
& clinical science



Site relationships
with rapid startup




Global footprint:
4,000+ across NA, EU,
LATAM, MENA & APAC

Active Next-Gen Oncology Experience


Operating both locally and globally across Phases I through III in a range of solid tumor and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge modalities.

Phase




■ Early Phase ■ Late Phase
■ Observational/LTFU

Indication



■ Solid ■ Heme

Drug Class



■ Immuno-Oncology ■ Other
■ Targeted Therapy



Worldwide
Clinical Trials

Oncology at Worldwide

Worldwide features a dedicated oncology business unit within our full-service global contract research organization. We partner with biopharmaceutical sponsors to deliver expert-led, globally scalable oncology trials across every phase of development. We help sponsors move fast with confidence and scale without disruption.

[Contact us](#) to learn how we can support your oncology program from FIH through registration.